Darolutamide with hormone therapy for prostate cancer after surgery
Part of Cancer, Kidney & urinary clinical trials.
This study looks at whether combining the drug darolutamide with standard hormone therapy can help men whose prostate cancer was found in their pelvic lymph nodes after prostate removal surgery. It aims to see if this treatment helps keep the cancer from coming back.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are male and between 18 and 80 years old.
- You have prostate cancer that was confirmed by a biopsy (pathology or cytology).
- Your cancer had spread to the lymph nodes in your pelvis (found when they were removed during surgery), but not to bones or other organs.
- You have not already received long-term prostate cancer treatment (like hormone therapy, chemo, or newer targeted pills) before joining this study.
- You do not have a rare type of prostate cancer (like small cell or neuroendocrine, as shown on your pathology report).
- You need to be in reasonably good health to participate (your doctor will assess this).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of two hormone therapies (darolutamide plus androgen deprivation therapy) given after surgery to remove the prostate, to see if it helps prevent the cancer from coming back in men with high-risk prostate cancer. The goal is to see if this treatment can keep the cancer from spreading or returning.
This study tests whether giving the drug darolutamide (with or without standard hormone therapy) before surgery helps shrink high-risk prostate cancer and reduce the chance of it coming back. If you qualify, you would receive the study treatment for a few months before your planned prostate removal surgery.
This trial tests giving a new hormone-blocking drug (darolutamide) plus standard hormone therapy before surgery for men with high-risk prostate cancer that has not spread. The goal is to see if this approach improves outcomes.
This Phase 3 trial tests whether adding darolutamide to standard hormone therapy and radiation works better than standard treatment alone for newly diagnosed prostate cancer that has spread to pelvic lymph nodes. If you qualify, you may receive darolutamide or a placebo alongside long-term hormone therapy and radiation.
This trial tests a combination of a hormone therapy pill (darolutamide) and a high-dose, precise form of radiation for men with localized prostate cancer that has high-risk features of coming back. The goal is to see if this approach is more effective than standard treatment.
This trial tests a new combination of drugs given before surgery for locally advanced prostate cancer. The goal is to see if giving these drugs first helps shrink the tumor and improves outcomes after surgery.
Hear when a new Prostate cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.